`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS LLC
`
`Petitioner
`
`V.
`
`ALCON RESEARCH, LTD
`Patent Owner
`
`Patent No. 8,791,154
`
`Issue Date: July 29, 2014
`Title: HIGH CONCENTRATION OLOPATADINE
`
`OPHTI-LALMIC COMPOSITION
`
`Inter Partes Review No. 2016-00544
`
`Affidavit of Christopher J. Mandernach in Support of
`Motion for Pro Hac Vice Admission Pursuant to 37 C.F.R. § 42.10(c)
`
`
`
`l.
`
`1, Christopher J. Mandernach, am more than twenty—one years of age,
`
`am competent to present this affidavit, and have personal knowledge of the facts
`
`set forth herein. I have over 7 years of patent litigation experience.
`
`2.
`
`This affidavit is given in support of the patent owner Alcon Research,
`
`Ltd. Motion for Pro Hac Vice Admission.
`
`3.
`
`I am a member in good standing of the bars of Minnesota and the
`
`District of Columbia.
`
`4.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`5.
`
`No court or administrative body has ever denied my application for
`
`admission to practice before it.
`
`6.
`
`No court or administrative body has ever imposed sanctions or
`
`contempt citations on me.
`
`7.
`
`I have read and will comply with the Office of Patent Trial Practice
`
`guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`8.
`
`I understand that I will be subject to the USPTO Code of Professional
`
`Responsibility set forth in 37 C.F.R. §§ ll.l0l et seq. and will be subject to
`
`disciplinary jurisdiction under 37 C.F.R. § ll.l9(a).
`
`9.
`
`I have applied to appear pro hac vice in 3 other proceedings before the
`
`Office in the last (3) years: (1) Apotex Corp. v. Alcon Research, Ltd, IPR20l3—
`
`
`
`00428, challenging U.S. Patent No. 8,268,299; (2) Apotex Corp. v. Alcon
`
`Research, Ltd., IPR20l3—0O429, challenging U.S. Patent No. 8,323,630; and (3)
`
`Apotex Corp. v. Alcon Research, Ltd, IPR20l3—O0430, challenging U.S. Patent
`
`No. 8,338,941.
`
`10.
`
`I am familiar with the subject matter at issue in the present
`
`proceeding. This familiarity comes from my experience representing Patent
`
`Owner as trial counsel in related district court litigation in the United States
`
`District Court for the District of Delaware in the following consolidated case:
`
`Alcon Research, Ltd. V. Watson Laboratories, Inc., Lupin Ltd, and Lupin
`
`Pharmaceuticals, Inc., Civil Action No. 15-1 l59—SLR-SRF (D. Del.).
`
`
`
`Christopher J. Mandernach
`
`Sworn to and subscribed before me
`
`this 2nd day of August, 2016.
`
`
`
`Notary Public
`
`“mo? i''-o\.\5:_',.
`
`‘ ,.